Zobrazeno 1 - 8
of 8
pro vyhledávání: '"629"'
Autor:
Emma Leena Alarmo, Philip Owens, Agnes E. Gorska, Anne Kallioniemi, Riikka Havunen, Harold L. Moses, Minna Ampuja
Publikováno v:
Cancer Research. 76:629-629
Background. Breast cancer is the most common cancer in women worldwide. Bone morphogenetic proteins (BMPs), members of the transforming growth factor β superfamily, are known to regulate cell proliferation, differentiation and motility, and have als
Autor:
F Andre, Thomas Filleron, Charlotte K.Y. Ng, Salvatore Piscuoglio, François Bertucci, Thomas Bachelot, Alexandra Jacquet, C Letourneau, M. Jimenez
Publikováno v:
Cancer Research. 79:GS1-08
Rationale: while large efforts have been done to characterize early breast cancer, little is known about the genomic landscape of metastatic breast cancer. In the present study, we performed whole exome sequencing of 800 metastatic breast cancers, in
Autor:
K Wride, IA Mayer, Jeffrey D. Isaacson, Denise A. Yardley, Kathy D. Miller, Komal Jhaveri, Jason B. Litten, MW Audeh, Chris Tankersley, A Knox, Mitch Raponi, Maysa M. Abu-Khalaf, Rita Nanda, DE Morganstern, Linda T. Vahdat, HS Rugo, CL Arteaga, Lajos Pusztai, Charles L. Vogel, Ravindranath Patel, RM Connolly, William J. Gradishar, Adam Brufsky, Lindsey Rolfe, S Sadeghi
Publikováno v:
Cancer Research. 77:P6-11
BACKGROUND: Lucitanib is a potent, oral antiangiogenic tyrosine kinase inhibitor of Vascular Endothelial Growth Factor Receptors 1-3 (VEGFR1-3), Platelet-Derived Growth Factor Receptors alpha and beta (PDGFRα/β), and Fibroblast Growth Factor Recept
Autor:
Sabine Kasimir-Bauer, Anna Christina Frackenpohl, Bahriye Aktas, Rainer Kimmig, Hans A. Kestler, Johann M. Kraus, Siegfried Hauch
Publikováno v:
Cancer Research. 75:P6-08
Introduction: Influence of lifestyle behaviour in risk of developing breast cancer is supported by several lines. Data from 632 early breast cancer (EBC) patients were collected to evaluate the influence of lifestyle factors in progression free survi
Autor:
Alex Friedlaender, Aurélie Ayme, Valérie Bonadona, Valeria Viassolo, Alexandre Bodmer, S. De Talhouet, Sana Intidhar Labidi-Galy, Pierre O. Chappuis, Adrien Buisson, Julien Péron, Aurelie Vuilleumier, Olivier Tredan
Publikováno v:
Cancer Research. 78:P3-03
Background: Germline mutations in BRCA1/BRCA2 genes increase the risk of breast and ovarian cancers. In ovarian cancer patients (pts) treated with platinum, BRCA1, and especially BRCA2, carriers have better survival than non-carriers. In breast cance
Publikováno v:
Cancer Research. 73:135-135
Background: There is experimental evidence supporting a dual role of coffee-related compounds on breast cancer development. Although reports from prospective epidemiologic studies do not support a relationship between coffee intake and breast cancer
Publikováno v:
Cancer Research. 72:2624-2624
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Purpose: To date, evaluation of the association of the ABO blood group and breast cancer has yielded mixed results. SNP [rs505922][1], located within the first intron
Autor:
S. Johnson, Alexey Manikhas, A. Florance, J. Maltzman, Andreas Makris, John Pippen, Louis Fehrenbacher, J. Ro, L. O'Rourke, Xavier Pivot
Publikováno v:
Cancer Research. 69:5094-5094
Background: EGF30008 was a double-blind, placebo-controlled phase III study which evaluated the benefit of adding lapatinib (L) to letrozole (Let) alone in patient (pts) with hormone receptor positive (HR+), metastatic breast cancer. Median progressi